$12.2 Billion is the total value of Baker Brothers Advisors's 119 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 19.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $4,559,485,000 | +93.5% | 34,110,011 | +45.2% | 37.31% | +61.5% |
| SGEN | Buy | Seattle Genetics, Inc. | $2,873,680,000 | +19.1% | 45,715,556 | +0.0% | 23.52% | -0.6% |
| ACAD | ACADIA Pharmaceuticals Inc. | $887,684,000 | +19.2% | 25,819,768 | 0.0% | 7.26% | -0.5% | |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $793,410,000 | -0.9% | 6,544,130 | +0.0% | 6.49% | -17.3% |
| GHDX | Buy | Genomic Health, Inc. | $433,648,000 | +7.2% | 13,770,982 | +0.0% | 3.55% | -10.6% |
| BMRN | BioMarin Pharmaceutical Inc. | $421,913,000 | +6.0% | 4,806,483 | 0.0% | 3.45% | -11.6% | |
| DBVT | DBV Technologies S.A.sponsored adr | $194,047,000 | +0.3% | 5,509,560 | 0.0% | 1.59% | -16.3% | |
| AQXP | Buy | Aquinox Pharmaceuticals, Inc. | $182,491,000 | +4.9% | 10,934,154 | +3.8% | 1.49% | -12.4% |
| BGNE | BeiGene, Ltd.sponsored adr | $134,475,000 | +20.6% | 3,673,175 | 0.0% | 1.10% | +0.6% | |
| AKAOQ | Achaogen, Inc. | $115,613,000 | +93.8% | 4,582,382 | 0.0% | 0.95% | +61.7% | |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $98,421,000 | +41.8% | 11,716,784 | +6.9% | 0.80% | +18.4% |
| BioMarin Pharmaceutical Inc.note 1.875% 4/23/2017 | $95,967,000 | +6.0% | 22,379,000 | 0.0% | 0.78% | -11.5% | ||
| AAAP | Buy | Advanced Accelerator Applications S.A.sponsored ads | $88,557,000 | +52.7% | 2,221,706 | +2.5% | 0.72% | +27.4% |
| NVTA | Invitae Corporation | $80,609,000 | +39.3% | 7,288,300 | 0.0% | 0.66% | +16.4% | |
| AMRN | Buy | Amarin Corporation plcsponsored adr new | $72,501,000 | +6.2% | 22,656,469 | +2.2% | 0.59% | -11.4% |
| ONCE | Spark Therapeutics, Inc. | $70,320,000 | +6.9% | 1,318,341 | 0.0% | 0.58% | -10.9% | |
| ACOR | Acorda Therapeutics, Inc. | $69,338,000 | +11.7% | 3,301,791 | 0.0% | 0.57% | -6.9% | |
| BLCM | Buy | Bellicum Pharmaceuticals, Inc. | $62,099,000 | -6.3% | 5,032,313 | +3.4% | 0.51% | -21.8% |
| CERS | Cerus Corporation | $58,087,000 | +2.3% | 13,053,275 | 0.0% | 0.48% | -14.7% | |
| EXEL | Sell | Exelixis, Inc. | $56,419,000 | +26.0% | 2,603,569 | -13.3% | 0.46% | +5.2% |
| New | Novavax, Inc.note 3.75% 2/1/2023 added | $48,554,000 | – | 108,500,000 | +100.0% | 0.40% | – | |
| HRTX | Buy | Heron Therapeutics, Inc. | $41,754,000 | +33.7% | 2,783,569 | +16.8% | 0.34% | +11.8% |
| NBIX | Neurocrine Biosciences, Inc. | $38,772,000 | +11.9% | 895,422 | 0.0% | 0.32% | -6.8% | |
| AVXS | Buy | AveXis, Inc. | $38,015,000 | +152.6% | 500,000 | +58.6% | 0.31% | +110.1% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $37,841,000 | +82.7% | 1,351,463 | +32.1% | 0.31% | +52.7% |
| VSAR | Sell | Versartis, Inc. | $35,454,000 | +23.9% | 1,660,593 | -13.5% | 0.29% | +3.2% |
| BLUE | bluebird bio, Inc. | $31,946,000 | +47.3% | 351,441 | 0.0% | 0.26% | +22.5% | |
| PGNX | Progenics Pharmaceuticals, Inc. | $29,744,000 | +9.3% | 3,150,808 | 0.0% | 0.24% | -9.0% | |
| Acorda Therapeutics, Inc.note 1.75% 6/15/2021 | $29,696,000 | +11.8% | 35,083,000 | 0.0% | 0.24% | -6.5% | ||
| MRUS | Merus N.V. | $28,293,000 | +15.5% | 1,160,014 | 0.0% | 0.23% | -3.3% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $25,408,000 | +64.9% | 10,286,483 | +0.1% | 0.21% | +37.7% |
| SGMO | Buy | Sangamo Therapeutics, Inc. | $23,561,000 | +90.5% | 4,530,901 | +11.7% | 0.19% | +59.5% |
| GLPG | Galapagos NVsponsored adr | $22,400,000 | +34.3% | 259,894 | 0.0% | 0.18% | +11.6% | |
| XNCR | Xencor, Inc. | $20,860,000 | -9.1% | 872,072 | 0.0% | 0.17% | -24.0% | |
| HALO | Halozyme Therapeutics, Inc. | $18,034,000 | +31.2% | 1,391,507 | 0.0% | 0.15% | +9.6% | |
| NeuroDerm Ltd. | $15,178,000 | +19.6% | 571,667 | 0.0% | 0.12% | 0.0% | ||
| NTLA | Intellia Therapeutics, Inc. | $14,965,000 | +7.5% | 1,062,120 | 0.0% | 0.12% | -10.3% | |
| SAGE | Sage Therapeutics, Inc. | $14,806,000 | +39.2% | 208,328 | 0.0% | 0.12% | +16.3% | |
| AIMT | Aimmune Therapeutics, Inc. | $14,644,000 | +6.3% | 673,908 | 0.0% | 0.12% | -11.1% | |
| DERM | Buy | Dermira, Inc. | $14,171,000 | +43.1% | 415,448 | +27.3% | 0.12% | +19.6% |
| ARRY | Sell | Array BioPharma Inc. | $14,178,000 | -37.6% | 1,585,913 | -38.7% | 0.12% | -48.0% |
| BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $13,830,000 | +0.7% | 12,228,000 | 0.0% | 0.11% | -16.3% | ||
| AERI | Aerie Pharmaceuticals, Inc. | $13,576,000 | +19.8% | 299,356 | 0.0% | 0.11% | 0.0% | |
| Sell | Aegerion Pharmaceuticals, Inc.note 2.0% 8/15/2019 | $13,241,000 | -30.7% | 16,517,000 | -37.7% | 0.11% | -42.2% | |
| FOMX | Foamix Pharmaceuticals Ltd. | $12,210,000 | -55.4% | 2,466,702 | 0.0% | 0.10% | -62.7% | |
| MRTX | Mirati Therapeutics, Inc. | $11,800,000 | +9.5% | 2,269,198 | 0.0% | 0.10% | -8.5% | |
| IMGN | ImmunoGen, Inc. | $11,669,000 | +89.7% | 3,015,353 | 0.0% | 0.10% | +58.3% | |
| LJPC | Buy | La Jolla Pharmaceutical Company | $11,317,000 | +4595.9% | 379,134 | +2658.1% | 0.09% | +4550.0% |
| CPRX | Catalyst Pharmaceuticals, Inc. | $9,949,000 | +85.7% | 5,102,153 | 0.0% | 0.08% | +52.8% | |
| ITCI | Intra-Cellular Therapies, Inc. | $9,899,000 | +7.7% | 609,166 | 0.0% | 0.08% | -10.0% | |
| ALKS | Alkermes plc | $8,790,000 | +5.3% | 150,251 | 0.0% | 0.07% | -12.2% | |
| ABEO | Abeona Therapeutics Inc. | $8,422,000 | +3.1% | 1,684,364 | 0.0% | 0.07% | -13.8% | |
| RIGL | Buy | Rigel Pharmaceuticals, Inc. | $8,337,000 | +73.5% | 2,518,882 | +24.8% | 0.07% | +44.7% |
| ACHN | Achillion Pharmaceuticals, Inc. | $7,816,000 | +1.9% | 1,856,637 | 0.0% | 0.06% | -14.7% | |
| LGND | Ligand Pharmaceuticals Incorporated | $7,767,000 | +4.2% | 73,386 | 0.0% | 0.06% | -12.3% | |
| AGIO | Agios Pharmaceuticals, Inc. | $7,514,000 | +40.0% | 128,666 | 0.0% | 0.06% | +15.1% | |
| CFRX | ContraFect Corporation | $7,283,000 | +2.9% | 4,045,876 | 0.0% | 0.06% | -13.0% | |
| INSM | Insmed Incorporated | $7,004,000 | +32.4% | 400,000 | 0.0% | 0.06% | +9.6% | |
| MGNX | MacroGenics, Inc. | $6,764,000 | -9.0% | 363,676 | 0.0% | 0.06% | -24.7% | |
| ASMB | Assembly Biosciences, Inc. | $6,373,000 | +109.8% | 250,000 | 0.0% | 0.05% | +73.3% | |
| CBAY | Buy | CymaBay Therapeutics, Inc. | $6,078,000 | +1036.1% | 1,413,499 | +357.0% | 0.05% | +900.0% |
| LOXO | Loxo Oncology, Inc. | $5,796,000 | +31.0% | 137,735 | 0.0% | 0.05% | +9.3% | |
| AKTX | Akari Therapeutics plcsponsored adr | $5,501,000 | +57.3% | 496,901 | 0.0% | 0.04% | +32.4% | |
| STML | Buy | Stemline Therapeutics, Inc. | $5,416,000 | +51.8% | 633,497 | +90.0% | 0.04% | +25.7% |
| RXDX | Ignyta, Inc. | $4,911,000 | +62.3% | 571,000 | 0.0% | 0.04% | +33.3% | |
| BIIB | Biogen Inc. | $4,511,000 | -3.6% | 16,500 | 0.0% | 0.04% | -19.6% | |
| ALDR | Alder BioPharmaceuticals, Inc. | $4,520,000 | 0.0% | 217,328 | 0.0% | 0.04% | -15.9% | |
| Array BioPharma Inc.note 3.0% 6/1/2020 | $4,258,000 | +1.5% | 3,000,000 | 0.0% | 0.04% | -14.6% | ||
| ANAB | New | AnaptysBio, Inc. | $4,163,000 | – | 150,000 | +100.0% | 0.03% | – |
| ZGNX | Sell | Zogenix, Inc. | $4,144,000 | -59.3% | 381,939 | -54.5% | 0.03% | -66.0% |
| NBRV | Nabriva Therapeutics AGsponsored adr | $4,200,000 | +101.3% | 350,000 | 0.0% | 0.03% | +70.0% | |
| EPZM | Epizyme, Inc. | $3,987,000 | +41.7% | 232,481 | 0.0% | 0.03% | +17.9% | |
| RARX | Ra Pharmaceuticals, Inc. | $3,789,000 | +40.2% | 177,952 | 0.0% | 0.03% | +19.2% | |
| RARE | Ultragenyx Pharmaceutical Inc. | $3,389,000 | -3.6% | 50,000 | 0.0% | 0.03% | -17.6% | |
| SYRS | Syros Pharmaceuticals, Inc. | $3,257,000 | +31.0% | 204,465 | 0.0% | 0.03% | +12.5% | |
| TRVN | Buy | Trevena, Inc. | $3,146,000 | +18.9% | 857,206 | +90.5% | 0.03% | 0.0% |
| Inotek Pharmaceuticals Corporationnote 5.75% 8/1/2021 | $3,008,000 | -41.8% | 5,000,000 | 0.0% | 0.02% | -51.0% | ||
| ADMS | Adamas Pharmaceuticals, Inc. | $3,021,000 | +3.6% | 172,630 | 0.0% | 0.02% | -13.8% | |
| GNMX | Buy | Aevi Genomic Medicine, Inc. | $3,010,000 | -34.0% | 1,618,089 | +83.8% | 0.02% | -44.4% |
| SNSS | Sunesis Pharmaceuticals, Inc. | $3,041,000 | +13.3% | 741,665 | 0.0% | 0.02% | -3.8% | |
| KPTI | Karyopharm Therapeutics Inc. | $2,786,000 | +36.6% | 216,990 | 0.0% | 0.02% | +15.0% | |
| Protalix BioTherapeutics, Inc.note 4.5% 9/15/2018 | $2,543,000 | +10.9% | 3,423,000 | 0.0% | 0.02% | -4.5% | ||
| Trillium Therapeutics Inc. | $2,544,000 | +8.9% | 413,697 | 0.0% | 0.02% | -8.7% | ||
| SELB | Selecta Biosciences, Inc. | $2,516,000 | -16.5% | 175,712 | 0.0% | 0.02% | -30.0% | |
| DMTX | Dimension Therapeutics, Inc. | $2,191,000 | -59.8% | 1,251,881 | 0.0% | 0.02% | -66.0% | |
| JNCE | New | Jounce Therapeutics, Inc. | $2,199,000 | – | 100,000 | +100.0% | 0.02% | – |
| TNXP | New | Tonix Pharmaceuticals Holdings Corp. | $2,099,000 | – | 449,500 | +100.0% | 0.02% | – |
| NTRA | Sell | Natera, Inc. | $2,028,000 | -30.5% | 228,676 | -8.3% | 0.02% | -41.4% |
| GLYC | GlycoMimetics, Inc. | $2,070,000 | -11.0% | 381,235 | 0.0% | 0.02% | -26.1% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $1,952,000 | +11.4% | 219,298 | 0.0% | 0.02% | -5.9% | |
| INFI | Infinity Pharmaceuticals, Inc. | $1,875,000 | +139.2% | 580,400 | 0.0% | 0.02% | +87.5% | |
| NVIV | InVivo Therapeutics Holdings Corp. | $1,620,000 | -3.6% | 400,000 | 0.0% | 0.01% | -18.8% | |
| AGLE | Sell | Aeglea BioTherapeutics, Inc. | $1,415,000 | -19.5% | 189,987 | -53.0% | 0.01% | -29.4% |
| MCRB | Seres Therapeutics, Inc. | $1,409,000 | +13.8% | 125,000 | 0.0% | 0.01% | 0.0% | |
| MDWD | MediWound Ltd. | $1,492,000 | +44.2% | 226,000 | 0.0% | 0.01% | +20.0% | |
| MYOK | MyoKardia, Inc. | $1,315,000 | +1.5% | 100,000 | 0.0% | 0.01% | -15.4% | |
| FLGT | Fulgent Genetics, Inc. | $1,365,000 | -5.6% | 125,000 | 0.0% | 0.01% | -21.4% | |
| CLLS | Cellectis S.A.sponsored ads | $1,200,000 | +41.5% | 50,000 | 0.0% | 0.01% | +25.0% | |
| CRBP | Sell | Corbus Pharmaceuticals Holdings, Inc. | $1,074,000 | -51.1% | 130,129 | -50.0% | 0.01% | -59.1% |
| JUNO | Sell | Juno Therapeutics, Inc. | $1,110,000 | -26.4% | 50,000 | -37.5% | 0.01% | -40.0% |
| AFMD | Affimed N.V. | $920,000 | +27.8% | 400,000 | 0.0% | 0.01% | +14.3% | |
| IMDZ | Immune Design Corp. | $1,013,000 | +23.7% | 148,937 | 0.0% | 0.01% | 0.0% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $890,000 | +3.4% | 57,762 | 0.0% | 0.01% | -12.5% | |
| CMRX | Chimerix, Inc. | $735,000 | +38.7% | 115,216 | 0.0% | 0.01% | +20.0% | |
| XLRN | Acceleron Pharma Inc. | $761,000 | +3.7% | 28,765 | 0.0% | 0.01% | -14.3% | |
| FPRX | Five Prime Therapeutics, Inc. | $696,000 | -27.8% | 19,247 | 0.0% | 0.01% | -33.3% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $551,000 | +36.0% | 100,000 | 0.0% | 0.01% | +25.0% | |
| PTN | Palatin Technologies, Inc. | $671,000 | -35.2% | 2,050,000 | 0.0% | 0.01% | -50.0% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $568,000 | -47.6% | 400,000 | 0.0% | 0.01% | -54.5% | |
| ABUS | Arbutus Biopharma Corporation | $587,000 | +32.8% | 180,582 | 0.0% | 0.01% | +25.0% | |
| DVAX | Dynavax Technologies Corporation | $446,000 | +50.7% | 75,000 | 0.0% | 0.00% | +33.3% | |
| PRTO | Sell | Proteon Therapeutics, Inc. | $523,000 | -29.3% | 298,591 | -23.3% | 0.00% | -42.9% |
| BIVV | New | Bioverativ Inc. | $449,000 | – | 8,249 | +100.0% | 0.00% | – |
| CCXI | ChemoCentryx, Inc. | $357,000 | -1.7% | 49,064 | 0.0% | 0.00% | -25.0% | |
| BDSI | BioDelivery Sciences International, Inc. | $399,000 | +8.4% | 210,021 | 0.0% | 0.00% | -25.0% | |
| WINT | Windtree Therapeutics, Inc. | $291,000 | -8.8% | 254,973 | 0.0% | 0.00% | -33.3% | |
| BPMX | New | BioPharmX Corporation | $191,000 | – | 377,295 | +100.0% | 0.00% | – |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $83,000 | +1.2% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $12,000 | -14.3% | 20,084 | 0.0% | 0.00% | – | |
| DNAI | Exit | ProNAi Therapeutics, Inc. | $0 | – | -200,000 | -100.0% | -0.00% | – |
| ALNY | Exit | Alnylam Pharmaceuticals, Inc. | $0 | – | -11,340 | -100.0% | -0.00% | – |
| FMI | Exit | Foundation Medicine, Inc. | $0 | – | -20,892 | -100.0% | -0.00% | – |
| Exit | Aptose Biosciences Inc. | $0 | – | -258,311 | -100.0% | -0.00% | – | |
| ALDX | Exit | Aldeyra Therapeutics, Inc. | $0 | – | -142,000 | -100.0% | -0.01% | – |
| TENX | Exit | Tenax Therapeutics, Inc. | $0 | – | -420,000 | -100.0% | -0.01% | – |
| PRQR | Exit | ProQR Therapeutics N.V. | $0 | – | -212,698 | -100.0% | -0.01% | – |
| CLCD | Exit | Colucid Pharmaceuticals, Inc. | $0 | – | -30,310 | -100.0% | -0.01% | – |
| QURE | Exit | uniQure N.V. | $0 | – | -230,000 | -100.0% | -0.01% | – |
| CNCE | Exit | Concert Pharmaceuticals, Inc. | $0 | – | -152,964 | -100.0% | -0.02% | – |
| SCYX | Exit | SCYNEXIS, Inc. | $0 | – | -467,600 | -100.0% | -0.02% | – |
| OSIR | Exit | Osiris Therapeutics, Inc. | $0 | – | -499,193 | -100.0% | -0.02% | – |
| ENTA | Exit | Enanta Pharmaceuticals, Inc. | $0 | – | -75,357 | -100.0% | -0.02% | – |
| IONS | Exit | Ionis Pharmaceuticals, Inc. | $0 | – | -57,140 | -100.0% | -0.03% | – |
| NERV | Exit | Minerva Neurosciences, Inc. | $0 | – | -258,805 | -100.0% | -0.03% | – |
| ADHD | Exit | Alcobra Ltd. | $0 | – | -2,336,359 | -100.0% | -0.05% | – |
| DSCI | Exit | Derma Sciences, Inc. | $0 | – | -3,752,390 | -100.0% | -0.19% | – |
| ABBV | Exit | AbbVie Inc. | $0 | – | -1,685,994 | -100.0% | -1.04% | – |
| Exit | Incyte Corporationnote 0.375% 11/15/2018 | $0 | – | -259,000,000 | -100.0% | -5.08% | – | |
| Exit | Incyte Corporationnote 1.25% 11/15/2020 | $0 | – | -274,500,000 | -100.0% | -5.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.